[go: up one dir, main page]

WO2003080034A3 - Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation - Google Patents

Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation Download PDF

Info

Publication number
WO2003080034A3
WO2003080034A3 PCT/EP2003/002984 EP0302984W WO03080034A3 WO 2003080034 A3 WO2003080034 A3 WO 2003080034A3 EP 0302984 W EP0302984 W EP 0302984W WO 03080034 A3 WO03080034 A3 WO 03080034A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
nanoparticles
solvent
microparticles
micronisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/002984
Other languages
English (en)
French (fr)
Other versions
WO2003080034A2 (de
Inventor
Bernd W Mueller
Norbert Rasenack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmatech GmbH
Original Assignee
Pharmatech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatech GmbH filed Critical Pharmatech GmbH
Priority to EP03724926A priority Critical patent/EP1487415A2/de
Priority to AU2003227540A priority patent/AU2003227540A1/en
Priority to US10/508,998 priority patent/US20050139144A1/en
Priority to JP2003577864A priority patent/JP2005527536A/ja
Publication of WO2003080034A2 publication Critical patent/WO2003080034A2/de
Publication of WO2003080034A3 publication Critical patent/WO2003080034A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Die vorliegende Erfindung beschreibt ein Verfahren zur Herstellung von Mikro- und/oder Nanoteilchen einer Substanz, bei dem molekular verteilte Substanz zu Teilchen assoziiert und gleichzeitig in Suspension stabilisiert wird, wobei die Substanz in einem Lösungsmittelsystem dafür gelöst wird und anschliessend ein Nicht-Lösungsmittel für diese Substanz, das mit dem Lösungsmittelsystem für diese Substanz mischbar ist, zugesetzt wird, wobei ein oder mehrere Kristallwachstumsinhibitor(en) zugegen ist (sind) und eine schnelle Vereinigung von Lösungsmittel und Nichtlösungsmittel durchgeführt wird, wodurch die Substanz unter Bildung einer Dispersion von Teilchen ausgefällt wird, die eine Grösse im Bereich Mikro- oder Nanometerbereich aufweisen.
PCT/EP2003/002984 2002-03-27 2003-03-21 Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation Ceased WO2003080034A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03724926A EP1487415A2 (de) 2002-03-27 2003-03-21 Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation
AU2003227540A AU2003227540A1 (en) 2002-03-27 2003-03-21 Method for the production and the use of microparticles and nanoparticles by constructive micronisation
US10/508,998 US20050139144A1 (en) 2002-03-27 2003-03-21 Method for the production and the use of microparticles and nanoparticles by constructive micronisation
JP2003577864A JP2005527536A (ja) 2002-03-27 2003-03-21 建設的な微細化によるミクロ粒子またはナノ粒子の調製プロセスおよび使用。

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214031.6 2002-03-27
DE10214031A DE10214031A1 (de) 2002-03-27 2002-03-27 Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation

Publications (2)

Publication Number Publication Date
WO2003080034A2 WO2003080034A2 (de) 2003-10-02
WO2003080034A3 true WO2003080034A3 (de) 2003-11-27

Family

ID=28050958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/002984 Ceased WO2003080034A2 (de) 2002-03-27 2003-03-21 Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation

Country Status (6)

Country Link
US (1) US20050139144A1 (de)
EP (1) EP1487415A2 (de)
JP (1) JP2005527536A (de)
AU (1) AU2003227540A1 (de)
DE (1) DE10214031A1 (de)
WO (1) WO2003080034A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE10355400A1 (de) 2003-11-25 2005-07-07 Noack, Andreas, Dr. Multikomponenten Mineralstoffpräparate und Verfahren zur Herstellung von Multikomponenten-Mineralstoffpräparaten
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
JP4870383B2 (ja) * 2005-05-06 2012-02-08 富士フイルム株式会社 ナノ粒子の濃縮方法
US8679341B2 (en) 2005-05-06 2014-03-25 Fujifilm Corporation Method of concentrating nanoparticles and method of deaggregating aggregated nanoparticles
DE102005027333B4 (de) 2005-06-13 2017-04-13 Terra Nano Ltd. Nanoskalische Reaktivdesorption - ein Verfahren zur Herstellung kolloidalisierter Wirkstoff- oder Vitalstoffspezies, insbesondere entsprechender Wirkstoff- oder Vitalstoffkonzentraten sowie Vorrichtungen zur Durchführung derselben
DE602006011910D1 (de) 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
CN101277682B (zh) * 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
EP1782797A1 (de) * 2005-11-02 2007-05-09 Pharmatex Italia Srl Verfahren zur Herstellung von sterilen pulverförmigen pharmazeutischen Verbindungen
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CA2631714C (en) * 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
KR20080111033A (ko) * 2006-03-29 2008-12-22 후지필름 가부시키가이샤 카제인 나노입자
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
JP5592647B2 (ja) * 2006-04-28 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 制御された析出による６，６−ジメチル−３−アザ−ビシクロ［３．１．０］ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080098900A1 (en) * 2006-11-01 2008-05-01 Babatunde Aremu Beverage manufacture using a static mixer
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
GB0707938D0 (en) * 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
GB0724498D0 (en) * 2007-12-15 2008-01-30 Univ Strathclyde Slow release compositions
EP2095816A1 (de) * 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension mit antifungaler Wirkung zur Verabreichung mittels Inhalation mit verbessertem Unreinheitsprofil und erhöhter Sicherheit
GB0806873D0 (en) * 2008-04-16 2008-05-21 Breath Ltd Steroid nebuliser formulation
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
RU2565438C2 (ru) * 2008-11-04 2015-10-20 Сипла Лимитед Фармацевтическая аэрозольная композиция
CN102369000A (zh) 2009-01-09 2012-03-07 前进制药公司 包含一种或多种富马酸酯的药用组合物
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US8834965B2 (en) * 2009-02-12 2014-09-16 Xerox Corporation Organoamine stabilized silver nanoparticles and process for producing same
GB0914231D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Dry powder inhaler formulations
WO2011116763A1 (de) 2010-03-22 2011-09-29 Mjr Pharmjet Gmbh Verfahren und vorrichtung zur herstellung von mikro- oder nanopartikeln
US8835363B2 (en) 2010-06-16 2014-09-16 Saudi Arabian Oil Company Drilling, drill-in and completion fluids containing nanoparticles for use in oil and gas field applications and methods related thereto
JP5977062B2 (ja) * 2011-03-30 2016-08-24 興和株式会社 カフェイン含有液状組成物及び該組成物を充填したカプセル剤
EP2782561A1 (de) 2011-11-24 2014-10-01 Synthon BV Partikel mit gesteuerter freisetzung mit dimethylfumarat
EP2601973A1 (de) * 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
AU2013203445C1 (en) 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
JP5827178B2 (ja) * 2012-06-05 2015-12-02 北越紀州製紙株式会社 セルロース多孔質体及びその製造方法
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
KR101466908B1 (ko) * 2013-05-20 2014-12-03 한국표준과학연구원 유리지방산 입자 분산액 및 유리지방산 입자 분산액의 제조방법
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
CN116617404A (zh) * 2023-03-30 2023-08-22 浙江萃泽医药科技有限公司 磷脂作为抑晶剂的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032095A1 (en) * 1995-04-13 1996-10-17 Astra Aktiebolag Process for the preparation of respirable particles
WO2001014036A1 (en) * 1999-08-19 2001-03-01 Aventis Pharma Limited Process for producing fine medicinal substances
US20030049323A1 (en) * 2001-08-29 2003-03-13 Hitt James E. Process to precipitate drug particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE4342625A1 (de) * 1993-12-14 1995-06-22 Max Planck Gesellschaft Pulverförmige Meliazeen-Extrakte
DE69509210T2 (de) * 1995-01-31 1999-09-16 Mitsubishi Chemical Corp., Tokio/Tokyo Verfahren zur Herstellung von pulverisiertem carboxylgruppenhaltigem Polymerisat
US20030148024A1 (en) * 2001-10-05 2003-08-07 Kodas Toivo T. Low viscosity precursor compositons and methods for the depositon of conductive electronic features

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032095A1 (en) * 1995-04-13 1996-10-17 Astra Aktiebolag Process for the preparation of respirable particles
WO2001014036A1 (en) * 1999-08-19 2001-03-01 Aventis Pharma Limited Process for producing fine medicinal substances
US20030049323A1 (en) * 2001-08-29 2003-03-13 Hitt James E. Process to precipitate drug particles
WO2003032951A1 (en) * 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GASSMANN P ET AL: "HYDROSOLS-ALTERNATIVES FOR THE PARENTERAL APPLICATION OF POORLY WATER SOLUBLE DRUGS", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 40, no. 2, 1 April 1994 (1994-04-01), pages 64 - 72, XP000441962, ISSN: 0939-6411 *
RUCH F ET AL: "Preparation of micrometer size budesonide particles by precipitation", JOURNAL OF COLLOID AND INTERFACE SCIENCE 01 SEP 2000 UNITED STATES, vol. 229, no. 1, 1 September 2000 (2000-09-01), pages 207 - 211, XP002253141, ISSN: 0021-9797 *
STECKEL H ET AL: "MICRONIZING OF STEROIDS FOR PULMONARY DELIVERY BY SUPERCRITICAL CARBON DIOXIDE", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 152, no. 1, 1997, pages 99 - 110, XP002052065, ISSN: 0378-5173 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Also Published As

Publication number Publication date
AU2003227540A1 (en) 2003-10-08
US20050139144A1 (en) 2005-06-30
WO2003080034A2 (de) 2003-10-02
JP2005527536A (ja) 2005-09-15
AU2003227540A8 (en) 2003-10-08
DE10214031A1 (de) 2004-02-19
EP1487415A2 (de) 2004-12-22

Similar Documents

Publication Publication Date Title
WO2003080034A3 (de) Verfahren zur herstellung und anwendung von mikro- und nanoteilchen durch aufbauende mikronisation
Lee et al. Characteristics of polymers enabling nano-comminution of water-insoluble drugs
Ghaderi et al. A new method for preparing biodegradable microparticles and entrapment of hydrocortisone in DL-PLG microparticles using supercritical fluids
Perrut et al. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes: Part I: Micronization of neat particles
Tu et al. Alginate microparticles prepared by spray–coagulation method: Preparation, drug loading and release characterization
CA2458889A1 (en) A process for preparing crystalline drug particles by means of precipitation
EP1280011A3 (de) Chemisch hergestellte Toner mit kontrollierter Teilchenform
WO2010015298A3 (de) Kristalline wirkstoff-mikropartikel, verfahren zu deren herstellung und verwendung in arzneimitteln
WO2007013889A3 (en) System and method for controlling the size and/or distribution of catalyst nanoparticles for nanostructure growth
JP2004262759A5 (de)
WO2006108637A3 (de) Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
Hanafy et al. Control of colloidal CaCO3 suspension by using biodegradable polymers during fabrication
EP1688169A4 (de) Verfahren zur herstellung von feinen teilchen einer organischen verbindung
WO2006137855A3 (en) Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
Tanimoto et al. Biomineralization-inspired fabrication of chitosan/calcium carbonates core-shell type composite microparticles as a drug carrier
EP1840151A8 (de) Dispersion von feinem polysilsesquioxanpartikel in organischem lösungsmittel, herstellungsverfahren dafür, wässrige dispersion von feinem polysilsesquioxanpartikel und herstellungsverfahren dafür
ATE553143T1 (de) Verfahren zur dispersion von feststoffteilchen in teilchenpolymeren
Zhang et al. Irbesartan drug formulated as nanocomposite particles for the enhancement of the dissolution rate
Dixit et al. Enhancing solubility and dissolution of olanzapine by spray drying using β-cyclodextrin polymer
ATE334159T1 (de) Verfahren zur herstellung von gut in wasser redispergierbaren und mit wasser benetzbaren polymerisatpulvern
WO2006015358A3 (en) Aqueous suspension of nanoscale drug particles from supercritical fluid processing
Jin et al. (Protamine/dextran sulfate) 6 microcapules templated on biocompatible calcium carbonate microspheres
EP1571181A3 (de) Anorganische feine Teilchen enthaltende Dispersion, Verfahren zu ihrer Herstellung, und Bildaufzeichnungsmaterial
Zheng et al. Preparation and properties of gelatin-chitosan/montmorillonite drug-loaded microspheres
WO2004108265A3 (en) Nanoparticles from supercritical fluid antisolvent process using particle growth and agglomeration retardants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10508998

Country of ref document: US

Ref document number: 2003577864

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003724926

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003724926

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642